Try our beta test site

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

This study has suspended participant recruitment.
(The study has reached the target number of patients to be treated but maybe expanded in the future.)
Sponsor:
Collaborator:
Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01860937
First received: May 21, 2013
Last updated: February 21, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: May 2018
  Estimated Primary Completion Date: May 2018 (Final data collection date for primary outcome measure)